{"id":827613,"date":"2025-03-19T12:38:42","date_gmt":"2025-03-19T16:38:42","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/biomx-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-25-2025\/"},"modified":"2025-03-19T12:38:42","modified_gmt":"2025-03-19T16:38:42","slug":"biomx-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-25-2025","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/biomx-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-25-2025\/","title":{"rendered":"BiomX to Report Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">NESS ZIONA, Israel, March  19, 2025  (GLOBE NEWSWIRE) &#8212; BiomX Inc. (NYSE American: PHGE) (\u201cBiomX\u201d or the \u201cCompany\u201d), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the Company will report fourth quarter and full year 2024 financial results and provide business and program updates on Tuesday, March 25, 2025.<\/p>\n<p align=\"left\">A press release reporting the results will be available in the Investors section of the Company\u2019s website at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=RmjWD2nQ-UKO9vseZMxhxoz1abYIs3YrKyFN24kmArWbMPNaArIoBXDWwvvk7wCSwOBeti-0KEgunbncfRxXRg==\" rel=\"nofollow\" target=\"_blank\">www.biomx.com<\/a>. The Company intends to host a conference call and a live audio webcast on a later date to report fourth quarter and full year 2024 financial results, in conjunction with its expected announcement of initial topline results from its Phase 2 trial for subjects with diabetic foot osteomyelitis.<\/p>\n<p align=\"left\">\n        <strong>About BiomX<\/strong><br \/>\n        <br \/>BiomX is a clinical-stage company leading the development of natural and engineered phage cocktails and personalized phage treatments designed to target and destroy harmful bacteria for the treatment of chronic diseases with substantial unmet needs. BiomX discovers and validates proprietary bacterial targets and applies its BOLT (\u201cBacteriOphage Lead to Treatment\u201d) platform to customize phage compositions against these targets. For more information, please visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=RmjWD2nQ-UKO9vseZMxhxs3ZTS-qwJKpi47Eh9UyNJbXlS7lOdU5l25p13bzJBF2VDG6TBX4w3pkOiSKZUtylA==\" rel=\"nofollow\" target=\"_blank\">www.biomx.com<\/a>, the content of which does not form a part of this press release.<\/p>\n<p align=\"left\">\n        <strong>BiomX, Inc.<\/strong><br \/>\n        <br \/>Ben Cohen<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=QP0dXvU8POqgaNaW7zmIXIQibFtmhvOkkQru3e7bKoiQaBf2kTyEOfNnmwHfkGjFIceYeXcsW8MQtMn8V-TZbA==\" rel=\"nofollow\" target=\"_blank\">benc@biomx.com<\/a><\/p>\n<p align=\"left\">\n        <strong>CORE IR<br \/><\/strong>Mike Mason<br \/>ir-biomx@biomx.com<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NzMzMyM2ODE0NDI5IzIyNTAxOTQ=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/YzViMzY1YTgtNzQwOS00ZDZlLWIxODctMTc5ZWI4ZTUyZDRhLTEyNjE3NDctMjAyNS0wMy0xOS1lbg==\/tiny\/BiomX.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>NESS ZIONA, Israel, March 19, 2025 (GLOBE NEWSWIRE) &#8212; BiomX Inc. (NYSE American: PHGE) (\u201cBiomX\u201d or the \u201cCompany\u201d), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the Company will report fourth quarter and full year 2024 financial results and provide business and program updates on Tuesday, March 25, 2025. A press release reporting the results will be available in the Investors section of the Company\u2019s website at\u00a0www.biomx.com. The Company intends to host a conference call and a live audio webcast on a later date to report fourth quarter and full year 2024 financial results, in conjunction with its expected announcement of initial topline results from its Phase 2 trial for &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/biomx-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-25-2025\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;BiomX to Report Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-827613","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>BiomX to Report Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/biomx-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-25-2025\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BiomX to Report Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NESS ZIONA, Israel, March 19, 2025 (GLOBE NEWSWIRE) &#8212; BiomX Inc. (NYSE American: PHGE) (\u201cBiomX\u201d or the \u201cCompany\u201d), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the Company will report fourth quarter and full year 2024 financial results and provide business and program updates on Tuesday, March 25, 2025. A press release reporting the results will be available in the Investors section of the Company\u2019s website at\u00a0www.biomx.com. The Company intends to host a conference call and a live audio webcast on a later date to report fourth quarter and full year 2024 financial results, in conjunction with its expected announcement of initial topline results from its Phase 2 trial for &hellip; Continue reading &quot;BiomX to Report Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/biomx-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-25-2025\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-19T16:38:42+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NzMzMyM2ODE0NDI5IzIyNTAxOTQ=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biomx-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-25-2025\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biomx-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-25-2025\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"BiomX to Report Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025\",\"datePublished\":\"2025-03-19T16:38:42+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biomx-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-25-2025\\\/\"},\"wordCount\":228,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biomx-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-25-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM5NzMzMyM2ODE0NDI5IzIyNTAxOTQ=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biomx-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-25-2025\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biomx-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-25-2025\\\/\",\"name\":\"BiomX to Report Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biomx-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-25-2025\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biomx-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-25-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM5NzMzMyM2ODE0NDI5IzIyNTAxOTQ=\",\"datePublished\":\"2025-03-19T16:38:42+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biomx-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-25-2025\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biomx-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-25-2025\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biomx-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-25-2025\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM5NzMzMyM2ODE0NDI5IzIyNTAxOTQ=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM5NzMzMyM2ODE0NDI5IzIyNTAxOTQ=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biomx-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-25-2025\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BiomX to Report Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"BiomX to Report Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/biomx-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-25-2025\/","og_locale":"en_US","og_type":"article","og_title":"BiomX to Report Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025 - Market Newsdesk","og_description":"NESS ZIONA, Israel, March 19, 2025 (GLOBE NEWSWIRE) &#8212; BiomX Inc. (NYSE American: PHGE) (\u201cBiomX\u201d or the \u201cCompany\u201d), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the Company will report fourth quarter and full year 2024 financial results and provide business and program updates on Tuesday, March 25, 2025. A press release reporting the results will be available in the Investors section of the Company\u2019s website at\u00a0www.biomx.com. The Company intends to host a conference call and a live audio webcast on a later date to report fourth quarter and full year 2024 financial results, in conjunction with its expected announcement of initial topline results from its Phase 2 trial for &hellip; Continue reading \"BiomX to Report Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/biomx-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-25-2025\/","og_site_name":"Market Newsdesk","article_published_time":"2025-03-19T16:38:42+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NzMzMyM2ODE0NDI5IzIyNTAxOTQ=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biomx-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-25-2025\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biomx-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-25-2025\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"BiomX to Report Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025","datePublished":"2025-03-19T16:38:42+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biomx-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-25-2025\/"},"wordCount":228,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biomx-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-25-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NzMzMyM2ODE0NDI5IzIyNTAxOTQ=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biomx-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-25-2025\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/biomx-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-25-2025\/","name":"BiomX to Report Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biomx-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-25-2025\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biomx-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-25-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NzMzMyM2ODE0NDI5IzIyNTAxOTQ=","datePublished":"2025-03-19T16:38:42+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biomx-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-25-2025\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/biomx-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-25-2025\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biomx-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-25-2025\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NzMzMyM2ODE0NDI5IzIyNTAxOTQ=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NzMzMyM2ODE0NDI5IzIyNTAxOTQ="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biomx-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-25-2025\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"BiomX to Report Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/827613","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=827613"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/827613\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=827613"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=827613"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=827613"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}